Free Trial
NASDAQ:IDYA

IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

IDEAYA Biosciences logo
$24.50 -0.33 (-1.33%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$24.50 +0.00 (+0.02%)
As of 07/25/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IDEAYA Biosciences Stock (NASDAQ:IDYA)

Key Stats

Today's Range
$24.23
$24.89
50-Day Range
$18.08
$24.83
52-Week Range
$13.45
$44.42
Volume
883,552 shs
Average Volume
970,209 shs
Market Capitalization
$2.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.55
Consensus Rating
Moderate Buy

Company Overview

IDEAYA Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

IDYA MarketRank™: 

IDEAYA Biosciences scored higher than 84% of companies evaluated by MarketBeat, and ranked 168th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IDEAYA Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about IDEAYA Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEAYA Biosciences is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEAYA Biosciences is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    IDEAYA Biosciences has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about IDEAYA Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    14.70% of the float of IDEAYA Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in IDEAYA Biosciences has recently increased by 2.12%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    IDEAYA Biosciences does not currently pay a dividend.

  • Dividend Growth

    IDEAYA Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.70% of the float of IDEAYA Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in IDEAYA Biosciences has recently increased by 2.12%, indicating that investor sentiment is decreasing.
  • News Sentiment

    IDEAYA Biosciences has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for IDEAYA Biosciences this week, compared to 6 articles on an average week.
  • Search Interest

    4 people have searched for IDYA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEAYA Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.50% of the stock of IDEAYA Biosciences is held by insiders.

  • Percentage Held by Institutions

    98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEAYA Biosciences' insider trading history.
Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDYA Stock News Headlines

HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
TD Cowen Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA)
See More Headlines

IDYA Stock Analysis - Frequently Asked Questions

IDEAYA Biosciences' stock was trading at $25.70 at the beginning of 2025. Since then, IDYA shares have decreased by 4.7% and is now trading at $24.50.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) posted its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.07.

IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

IDEAYA Biosciences' top institutional investors include Platinum Investment Management Ltd. (0.19%), KLP Kapitalforvaltning AS (0.02%), Palumbo Wealth Management LLC (0.02%) and Vanguard Personalized Indexing Management LLC (0.01%). Insiders that own company stock include Yujiro S Hata, Briseno Andres Ruiz, Paul A Stone, Michael Anthony White and Jason Throne.
View institutional ownership trends
.

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/06/2025
Today
7/26/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IDYA
CIK
1676725
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$68.00
Low Price Target
$25.00
Potential Upside/Downside
+94.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$274.48 million
Net Margins
N/A
Pretax Margin
-4,386.90%
Return on Equity
-29.28%
Return on Assets
-27.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.92
Quick Ratio
13.92

Sales & Book Value

Annual Sales
$7 million
Price / Sales
306.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.25 per share
Price / Book
2.00

Miscellaneous

Outstanding Shares
87,580,000
Free Float
85,392,000
Market Cap
$2.15 billion
Optionable
Optionable
Beta
0.03
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:IDYA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners